SCHEMBL10209463

SCHEMBL10209463

CC1=NC2(C(=O)N1C)c1cc(O)ccc1CC1CCOC[C@@H]12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 15/20 0.53
BACE1 P56817 15/20 0.53
OPRM1 P35372 2/20 0.35
SIGMAR1 Q99720 2/20 0.34
TMEM97 Q5BJF2 1/20 0.34
GRIN2D O15399 2/20 0.33
GRIN3B O60391 2/20 0.33
SLC6A4 P31645 2/20 0.33
OPRD1 P41143 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN2C Q14957 2/20 0.33
GRIN3A Q8TCU5 2/20 0.33
SLC22A1 O15245 1/20 0.33
ADRA2A P08913 1/20 0.33
SCN1A P35498 1/20 0.33
OPRK1 P41145 1/20 0.33
KCNH2 Q12809 1/20 0.33
MRGPRX2 Q96LB1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892429 0.89 BACE1 (0.66) CTSDBACE1
SCHEMBL10209455 0.89 BACE1 (0.66) CTSDBACE1
SCHEMBL892159 0.84 CTSD (0.49) CTSDBACE1OPRM1SIGMAR1TMEM97
SCHEMBL892158 0.84 CTSD (0.49) CTSDBACE1OPRM1SIGMAR1TMEM97
SCHEMBL10209459 0.81 BACE1 (0.49) CTSDBACE1
SCHEMBL882561 0.75 BACE1 (0.64) CTSDBACE1
SCHEMBL891952 0.75 BACE1 (0.64) CTSDBACE1
SCHEMBL891960 0.71 BACE1 (0.72) CTSDBACE1
SCHEMBL10209587 0.69 BACE1 (1.00) CTSDBACE1
Trifluoroacetic Acid SCHEMBL892353 0.68 BACE1 (0.64) CTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 CTSD 224/4885BACE1 1/4885OPRM1 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.